Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Binimetinib plus Pembrolizumab in BRAF V600E/K Mutation-Positive Melanoma
NCT04657991Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of encorafenib, binimetinib in melanoma, sponsored by Pfizer. Started Jan 2021; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04657991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657991.